149 related articles for article (PubMed ID: 10396496)
1. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.
Lord J; Thomason MJ; Littlejohns P; Chalmers RA; Bain MD; Addison GM; Wilcox AH; Seymour CA
J Epidemiol Community Health; 1999 Mar; 53(3):179-86. PubMed ID: 10396496
[TBL] [Abstract][Full Text] [Related]
2. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism.
Geelhoed EA; Lewis B; Hounsome D; O'leary P
J Paediatr Child Health; 2005 Nov; 41(11):575-9. PubMed ID: 16398841
[TBL] [Abstract][Full Text] [Related]
4. [A cost-benefit evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism].
Gu X; Wang J; Ye J; Cheng X
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 May; 34(3):147-9. PubMed ID: 11860921
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
[TBL] [Abstract][Full Text] [Related]
6. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of establishing a neonatal screening programme for phenylketonuria in Libya.
Sladkevicius E; Pollitt RJ; Mgadmi A; Guest JF
Appl Health Econ Health Policy; 2010; 8(6):407-20. PubMed ID: 21043542
[TBL] [Abstract][Full Text] [Related]
8. [Comparative presentation of current economic evaluation studies for phenylketonuria screening].
Ahrens D; Güntert B; Brand A
Gesundheitswesen; 1999 Apr; 61(4):190-6. PubMed ID: 10408146
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism.
Dhondt JL; Farriaux JP; Sailly JC; Lebrun T
J Inherit Metab Dis; 1991; 14(4):633-9. PubMed ID: 1749228
[TBL] [Abstract][Full Text] [Related]
10. Economics of tandem mass spectrometry screening of neonatal inherited disorders.
Pandor A; Eastham J; Chilcott J; Paisley S; Beverley C
Int J Technol Assess Health Care; 2006; 22(3):321-6. PubMed ID: 16984060
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of tandem mass spectrometry screening in California.
Feuchtbaum L; Cunningham G
Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
[TBL] [Abstract][Full Text] [Related]
12. Health economic analysis of the neonatal screening program in Japan.
Hisashige A
Int J Technol Assess Health Care; 1994; 10(3):382-91. PubMed ID: 8071001
[TBL] [Abstract][Full Text] [Related]
13. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
Grosse SD; Thompson JD; Ding Y; Glass M
Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561
[TBL] [Abstract][Full Text] [Related]
14. Newborn screening for inborn errors of metabolism: a systematic review.
Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Newborn Screening for Phenylketonuria and Congenital Hypothyroidism.
Appelberg K; Sörensen L; Zetterström RH; Henriksson M; Wedell A; Levin LÅ
J Pediatr; 2023 May; 256():38-43.e3. PubMed ID: 36495999
[TBL] [Abstract][Full Text] [Related]
16. The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.
Rothschild MI; Russ R; Brennan KA; Williams CJ; Berrones D; Patel B; Martinez-Castellanos MA; Fernandes A; Hubbard GB; Chan RVP; Yang Z; Olsen TW
Am J Ophthalmol; 2016 Aug; 168():110-121. PubMed ID: 27130372
[TBL] [Abstract][Full Text] [Related]
17. Costs of different strategies for neonatal hearing screening: a modelling approach.
Boshuizen HC; van der Lem GJ; Kauffman-de Boer MA; van Zanten GA; Oudesluys-Murphy AM; Verkerk PH
Arch Dis Child Fetal Neonatal Ed; 2001 Nov; 85(3):F177-81. PubMed ID: 11668159
[TBL] [Abstract][Full Text] [Related]
18. Health economic issues of screening programmes.
Wildner M
Eur J Pediatr; 2003 Dec; 162 Suppl 1():S5-7. PubMed ID: 14595558
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
Cipriano LE; Rupar CA; Zaric GS
Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
